International

Latest immunisation news from around the world

20 Feb 2015
Protection against HPV types 31, 33, 45, 52, and 58 in Gardasil 9 can prevent 20 percent more cervical, vulvar, and vaginal cancers than the Gardasil vaccine. Both Gardasil 9 and Gardasil protect against the potential cancer causing HPV types 16 and 18 and against genital warts caused by HPV types 6 and 11. Oral and anal cancers in men and women...
10 Dec 2014
The vaccine covers the same four human papillomaviruses (HPVs) as Gardasil plus an additional five types known to cause approximately 20 percent of cervical cancers  (HPV 31, 33, 45, 52, 58). The course for Gardasil 9 is three immunisations over a six month period, following the same schedule as Gardasil. The vaccine has a similar safety profile...
27 Nov 2014
The Vaccine Safety Network (VSN) is part of the World Health Organization. It provides endorsement for vaccine and immunisation related websites who meet a strict set of criteria regarding balanaced and understandable information for communities. In order to underscore the diversity of the VSN and recognise each member’s efforts to provide users...
12 Aug 2014
The Inaugural New Zealand Influenza Symposium, November 12th 2014 Tamaki Campus, The University of Auckland. We are pleased to announce a new opportunity for our clinical and academic colleagues-a one day symposium focussing upon influenza and vaccine strategies for NZ. Influenza remains a significant challenge- its chimeric changes and seemingly...
03 Jul 2014
Reassurance of vaccine safety remains critical for population health. A recent systematic review published in Paediatrics examined the literature on the safety of routine vaccines for children in the US. While they did confirm a link between vaccines and known serious adverse events, they were able to confirm that these events are extremely rare....
29 Oct 2013
The World Health Organization (WHO) have reported a cluster of 22 cases of acute flaccid paralysis with laboratory investigation of 10 of these cases identifying wild poliovirus type 1. Most of the cases are children under two years of age who were unimmunised or had not completed their primary course of polio immunisations.  The WHO identifies...
15 Aug 2013
The next steps will involve the Australian Technical Advisory Group on Immunisation making recommendations of who should receive the vaccine on the National Immunisation Programme to the Minister for Health and Ageing, and Novartis working with regulatory authorities to make the vaccine available for private purchase in Australia. Meningococcal...
27 Mar 2013
The book, published in January 2013, is based on infromation provided by the HistoryofVaccines.org website which is well worth a visit even if only to watch the animated timeline showing the history of diseases, epidemics, vaccine discovery and development and public health measures to protect people against disease. The book is only available...
25 Jan 2013
In Europe, the vaccine has been licensed for use in individuals two months of age and older. The Therapeutic Goods Administration (TGA) in Australia is also reviewing the vaccine data and considering licensure of Bexsero® in Australia. Bexsero® will complement the currently available meningococcal group C and groups A, C, Y and W-135 vaccines...
03 Dec 2012
The New Zealand arm of the Global Poverty Project will be launching a number of new and exciting initiatives in 2013 centred around the worldwide elimination of polio. Their aim is to increase public engagement in The End of Polio campaign and celebrate the phenomenal efforts of Rotary, UNICEF and others. Details of events will be available on...